viewTodos Medical Ltd.

Todos Medical updates on Phase 2 trial progress to treat hospitalized coronavirus patients in Israel

Todos Medical Ltd (OTCQB:TOMDF) CEO Gerald Commissiong updated Proactive on progress of enrollment of its Phase 2 clinical trial to treat hospitalized coronavirus patients in Israel, with its TolloTest biomarker being used for the first time as a surrogate biomarker to monitor patient response to treatment.

Commissiong says recruitment is 'picking up again' due to an increase in coronavirus caseload in Israel.

The medical diagnostics and related solutions company also said its partners at NLC Pharma have identified an anti-inflammatory mechanism of action for its Tollovir dietary supplement to complement its 3CL protease inhibiting mechanism. Tollovid, a mix of botanical extracts, is being targeted to support healthy immune function against circulating coronaviruses.

Quick facts: Todos Medical Ltd.


Price: 0.041 USD

Market Cap: $24.7 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...


Todos Medical accepting cryptocurrency to purchase Tollovid and Tollovid...

Todos Medical Ltd CEO Gerald Commissiong tells Proactive New York it biotechnology group is now accepting Bitcoin, Ethereum, Dogecoin, Bitcoin Cash, and Litecoin as payment for its proprietary 3CL protease inhibitor wellness products Tollovid and Tollovid Daily. Commissiong says the group has...

1 week, 1 day ago

2 min read